Cheng Du Sheng Nuo Biotec Co. Ltd. A Cash Flow Conversion Efficiency

Latest as of September 2025: -0.021x

Cheng Du Sheng Nuo Biotec Co. Ltd. A cash flow conversion efficiency. Based on the latest financial reports, Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) has a cash flow conversion efficiency ratio of -0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-21.56 Million ≈ $-3.15 Million USD) by net assets (CN¥1.03 Billion ≈ $151.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Cheng Du Sheng Nuo Biotec Co. Ltd. A (2017–2024)

Cash flow conversion efficiency of Cheng Du Sheng Nuo Biotec Co. Ltd. A from 2017 to 2024. This chart illustrates how Cheng Du Sheng Nuo Biotec Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Cheng Du Sheng Nuo Biotec Co. Ltd. A share price for real-time trading data and today's change.

Cheng Du Sheng Nuo Biotec Co. Ltd. A Cash Flow Conversion Ratio Explained

Cheng Du Sheng Nuo Biotec Co. Ltd. A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Cheng Du Sheng Nuo Biotec Co. Ltd. A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cheng Du Sheng Nuo Biotec Co. Ltd. A ranked by their cash flow conversion efficiency. Also see 688117 market cap for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Guggenheim Taxable Municipal Managed Duration Trust
NYSE:GBAB
0.033x
Beijing Hanbang Technology Corp
SHE:300449
-0.118x
RFG Holdings Ltd
JSE:RFG
0.121x
Kambi Group Plc
F:7KB
0.089x
Atea Pharmaceuticals Inc
NASDAQ:AVIR
-0.182x
Qumei Furniture Group Co Ltd
SHG:603818
0.062x
SPCG Public Company Limited
BK:SPCG
0.013x
Zoneco Group Co Ltd
SHE:002069
0.181x

Annual Cash Flow Conversion Efficiency for Cheng Du Sheng Nuo Biotec Co. Ltd. A (2017–2024)

The table below shows the annual cash flow conversion efficiency of Cheng Du Sheng Nuo Biotec Co. Ltd. A from 2017 to 2024. Review 688117 free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥918.32 Million
≈ $134.38 Million
CN¥25.27 Million
≈ $3.70 Million
0.028x -72.01%
2023-12-31 CN¥880.10 Million
≈ $128.79 Million
CN¥86.53 Million
≈ $12.66 Million
0.098x -14.99%
2022-12-31 CN¥826.74 Million
≈ $120.98 Million
CN¥95.62 Million
≈ $13.99 Million
0.116x +73.26%
2021-12-31 CN¥785.14 Million
≈ $114.89 Million
CN¥52.41 Million
≈ $7.67 Million
0.067x -63.87%
2020-12-31 CN¥437.57 Million
≈ $64.03 Million
CN¥80.84 Million
≈ $11.83 Million
0.185x +124.95%
2019-12-31 CN¥376.46 Million
≈ $55.09 Million
CN¥30.92 Million
≈ $4.52 Million
0.082x -59.40%
2018-12-31 CN¥327.35 Million
≈ $47.90 Million
CN¥66.23 Million
≈ $9.69 Million
0.202x -16.00%
2017-12-31 CN¥241.74 Million
≈ $35.37 Million
CN¥58.22 Million
≈ $8.52 Million
0.241x --

About Cheng Du Sheng Nuo Biotec Co. Ltd. A

SHG:688117 China Drug Manufacturers - Specialty & Generic
Market Cap
$345.69 Million
CN¥2.36 Billion CNY
Market Cap Rank
#13816 Global
#4091 in China
Share Price
CN¥15.01
Change (1 day)
-2.91%
52-Week Range
CN¥14.14 - CN¥46.10
All Time High
CN¥48.78
About

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide,… Read more